Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.

The Department of Health and Human Services under Robert F. During his Senate confirmation hearings, Health Secretary Robert ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

RSV seasons ended earlier than usual in 2022-23 and 2023-24, and typical human hMPV circulation patterns have returned since the COVID-19 pandemic.

Health and Human Services Secretary Robert F. Kennedy Jr. Vaccine Advisers Sow Doubts as Scientists Protest U.S. Pivot on ...

The Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), and its eight new ...

As fired and retired scientists rallied outside in the Atlanta heat, an advisory panel that Robert F. Kennedy Jr. handpicked ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization ...

RSV is the focus of a new national pediatric guideline in China aimed at standardizing diagnosis, treatment, and prevention strategies for respiratory tract infections in children ...